Gilead posts positive Q1 buoyed by HIV drug growth - Pharmaceutical Technology

Biktarvy continues to be a strong growth asset for Gilead, while Yeztugo’s launch rides an upward trajectory. Biktarvy continues to be a strong growth asset for Gilead, while Yeztugo’s launch rides an upward trajectory. Gilead’s HIV portfolio was a strong growth area for the company in Q1 2026. Credit: Tada Images / Shutterstock.com. Gilead Sciences has secured a good start to 2026 with its human immunodeficiency (HIV) medicines amid the backdrop of a generally positive first quarter. During Q1 2026, Gilead’s total revenue took a 4% upturn year-on-year (YoY) to $7bn, exceeding the analyst consensus. Of the $6.9bn in total…

Source: Pharmaceutical Technology